Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases

<div>Mean sclerostin concentrations with standard error of the mean (SEM) in patients with castration-sensitive prostate cancer (CSPC) or castration-resistant prostate cancer (CRPC).</div>

Disease Markers

fig4

Figure 4

Figure 4: Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases 